Doctronic navigation menu Log In
Doctronic navigation menu

Contents
  • First-Line Treatments
  • Advanced Options
  • Innovative Therapies

How is Cutaneous Lupus Treated?

How is Cutaneous Lupus Treated?

What's This About?

Treating cutaneous lupus involves various strategies to manage symptoms and prevent skin damage. Let's explore the options available.
Contents
  • First-Line Treatments
  • Advanced Options
  • Innovative Therapies

First-Line Treatments

Photoprotection is crucial, as UV light can worsen the condition. Topical corticosteroids and calcineurin inhibitors are commonly used to reduce inflammation. Antimalarial drugs like hydroxychloroquine are often prescribed, showing benefits in skin symptom management.

Advanced Options

For those who don't respond to first-line treatments, immunomodulatory agents like methotrexate and mycophenolate mofetil may be used. Thalidomide and lenalidomide are other options, though they require careful monitoring due to possible side effects.
Cutaneous lupus is an autoimmune disease affecting the skin, characterized by inflammation and damage due to an overactive immune response.

Innovative Therapies

New treatments like JAK inhibitors and biologics such as rituximab are being explored for their effectiveness in cutaneous lupus. These therapies offer hope for patients with treatment-resistant cases.

FAQs

What is the first step in treating cutaneous lupus?

Photoprotection and topical treatments are the first steps.

Are there advanced treatment options for severe cases?

Yes, immunomodulatory agents and biologics are available.

Can antimalarials help with cutaneous lupus?

Yes, they are often used to manage skin symptoms.

What new treatments are being explored?

JAK inhibitors and biologics like rituximab are promising.

The Bottom Line

A variety of treatments exist for cutaneous lupus, from traditional to innovative therapies.
Explore the best treatment options for cutaneous lupus with Doctronic's guidance!
Additional References
  1. Chasset F, Bouaziz JD, Costedoat-Chalumeau N, et al. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol 2017; 177:188.
  2. Riley K, Schwager Z, Stern M, et al. Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. JAMA Dermatol 2019; 155:491.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic.